Abiopharma

🔍 Advaithi Revathi (Director)

Company: FLEX LTD. (FLEX)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 255,062 shares of Ordinary Shares (Direct)
  Date: 2026-05-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 803,112.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,200 shares of Ordinary Shares at $138.4236 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 796,912.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 8,665 shares of Ordinary Shares at $139.3175 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 788,247.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 12,013 shares of Ordinary Shares at $140.2616 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 776,234.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 8,589 shares of Ordinary Shares at $141.1286 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 767,645.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 13,770 shares of Ordinary Shares at $142.4088 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 753,875.00 | transaction_form_type: 4 | Footnotes: F2, F7
• Sold 37,381 shares of Ordinary Shares at $143.2718 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 716,494.00 | transaction_form_type: 4 | Footnotes: F2, F8
• Sold 27,420 shares of Ordinary Shares at $144.2669 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 689,074.00 | transaction_form_type: 4 | Footnotes: F2, F9
• Sold 52 shares of Ordinary Shares at $144.815 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 689,022.00 | transaction_form_type: 4 | Footnotes: F2, F10
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-05-08 | Code: H | nature_of_ownership: By GRAT | shares_owned_after: 815,262.00 | Footnotes: F12

Footnotes:

• F1: On June 14, 2023, the Reporting Person was awarded performance-based restricted share units ("PSUs") within a preset range, with the actual number contingent upon the achievement of a certain performance criterion with respect to the three-year performance period ending on March 31, 2026. The Issuer certified the achievement of the performance criterion, and the PSUs fully vested, on May 8, 2026, and were subject to applicable taxes upon delivery.
• F2: The sales reported in this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs.
• F3: Price reflects weighted average sales price; actual sales prices ranged from $137.785 to $138.765. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F4: Price reflects weighted average sales price; actual sales prices ranged from $138.79 to $139.78. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F5: Price reflects weighted average sales price; actual sales prices ranged from $139.79 to $140.785. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F6: Price reflects weighted average sales price; actual sales prices ranged from $140.79 to $141.78. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F7: Price reflects weighted average sales price; actual sales prices ranged from $141.795 to $142.79. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F8: Price reflects weighted average sales price; actual sales prices ranged from $142.81 to $143.80. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F9: Price reflects weighted average sales price; actual sales prices ranged from $143.815 to $144.79. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F10: Includes the following: (1) 109,478 unvested RSUs, which will vest in two equal annual installments beginning on June 12, 2026; (2) 94,675 unvested RSUs, which will vest in three equal annual installments beginning on June 12, 2026; and (3) 85,021 unvested RSUs, which will vest on June 14, 2026.
• F11: Each unvested RSU represents a contingent right to receive one unrestricted, fully transferable share for each vested RSU which has not been previously forfeited.
• F12: Reflects the transfer by the Reporting Person of 815,262 directly owned ordinary shares to a grantor retained annuity trust ("GRAT"), which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Exchange Act.